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Introduction
As is well known the drug discovery 
and development process is a 
complex process typically starting 
from the target identification and 
validation of a target to progress to 
clinical studies and hopefully ending 
with a new drug to the market 
[Figure 1]. 
 In this process, different 
approaches and methods are 
required to understand the 
disease’s mechanisms, to profile hit 
molecules that will be progressed 
to leads suitable for full scale lead 
optimization programmes and then 
to generate quality drug candidates 
to advance to clinical studies.
Focusing on small molecules’ drugs 
and on hit to candidate phases, a 
variety of techniques will be used 
to study the compounds’ profiles 
at different levels including the 
physicochemical profiles, purity, 
solid state behaviours and structures 
to ensure a quality hit/lead/
candidate and related data to allow 
understanding of the mechanism of 
action and SAR correlation.
Nuclear Magnetic Resonance (NMR) 
spectroscopy will play a pivotal role 
generating data on the molecular 
interactions between ligands and 
biological targets, in addition to 
providing the structures of drug 
molecules, by-products, impurities, 
metabolites and quantification data.
NMR Screening Impact
During the drug discovery phase, 
NMR spectroscopy is becoming more 
and more relevant with application at 
multiple stages along the progression 
of a project: NMR experiments 
are used for hits generation, 
lead discovery and optimization, 
evaluation of in vitro/in vivo selectivity 
and efficacy, studies drug toxicity 
profiles and identification of new 
drug discovery targets.
 Over the last years there has been 
a large increase in the application 
of NMR techniques for the rapid 
determination of protein-ligand 
structures and interactions, to 
powerfully screen fragment-based 
libraries, to identify biological 
relevant ligand interactions, and to 
monitor changes in the metabolome 
from bio-fluids and cells to explore 
compounds activity. 
 Focusing on the NMR-based 
screening techniques, the NMR 
experiments could be divided into 
two main categories: target observed 
and ligand observed methods.
Without doubt, high resolution 
protein structure is a key requirement 
to evaluate the biological relevance 
of a hit from screening and HTS (high-
throughput screening) and NMR 
together with X-ray are playing an 
essential role.
 The last period has witnessed the 
generation of fast NMR sequences 
and methods to allow a faster 
impact on the drug discovery project 
time but the NMR target-observed 
techniques still require time, material, 
possible labelling and difficulties in 
handling a number of different hits 
and studies on mixtures.
 Nevertheless, if the resonance 
assignment of the labelled target is 
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known, the exploitation of differences 
in chemical shifts between free and 
bound target in two dimensional 
correlation spectra (shift mapping) 
will provide important structural 
information on the site of binding. 
The experiments could be also be 
of high value on selectively labelled 
target decreasing the spectra 
complexity and so increasing the size 
of the target that could be studied by 
NMR techniques.
 Considering now that the chemical 
shift is highly sensitive to the 
environment of the atom and, as a 
consequence, it provides information 
on the binding of a small molecule to 
a biological target, and on which part 
of the molecule is interacting and 
where, it is clear that ligand-observed 
techniques could generate proof and 
data for the binding understanding 
and profile.
 In addition, other experiments 
based on molecule relaxation values 
are sensitive to the motion of the 
compound (free vs bound state) and 
together these experiments will allow 
validation of ligand binding and/
or identification of ligands also in 
mixtures.
 The ligand observed techniques 
benefit of:
•	 one-dimensional experiments;
•	 detection of the ligand’s signals 
(facilitating also the mixture 
analysis);
•	 smaller amount of target substrate;
•	 structural and binding information 
of the ligand;
•	 detection of week binding ligands;
•	 limited restrictions on size and type 
of the target, with no isotope 
labelling requirement or target 
information details.
 On the undesirable side, the 
techniques could generate false 
negatives (strong binding and slow 
exchange equilibria) or false positives 
(unspecific binding) but all these 
aspects could be further studied to 
result in a substantiated answer.
During the Hits generation 
phase, NMR will be used for the 
determination of binding affinity 
values toward the hit validation step 
to generate a lead where the NMR 
experiments will also remove the 
false positives and locate the binding 
site (for example within the FBDD 
approach). In the lead optimization 
phase, to improve potency of the 
compounds, the epitope mapping 
will be determined, together with the 
conformation of the bound ligand, 
while in the late lead optimization 
stage for the candidate selection the 
NMR will support the bioavailability, 
ADME, PK and toxicological 
experiments.
The combination of NMR screening 
methods with other techniques, 
such as in silico computational 
protocol, X-ray crystallography, 
and biophysical experiments will 
decrease the number of compounds 
to be studied generating filters and 
resulting in time and cost saving 
and efficiency increase. The NMR will 
be so used to screen and profile a 
library (or set) of compounds with the 
unique ability of providing proof for 
binding between the ligand and the 
biological target and subsequently 
being able to detect the binding site 
and determining the construct of the 
complex. 
 This short note will not include 
technical details of the many NMR-
based methods that could be found 
in several papers and reviews across 
the last decade [1-8].
 The versatility of the NMR 
techniques is allowing the detection 
of target-ligand interactions through 
a large variety of measurements. 
The insights will derive from the 
observation of peak intensity and/
or line-width changes, saturation 
transfer differences (STD), chemical 
shifts perturbations, R2 relaxation 
effects, R1, sel competition data, 
induced transferred NOEs, interligand 
NOEs, diffusion coefficient 
measurements and changes, and, 
in general, from monitoring any 
changes in the NMR spectra resulting 
from the ligand-target interactions.
 A big impact of the NMR techniques 
is also evident on the “undruggable” 
targets when other techniques 
alone fail to result in relevant data 
and studies on protein-protein, 
protein-membrane macromolecular 
recognition are now becoming more 
and more frequently successfully 
progressed [9].
 The lead compound will need then 
to be optimized in the bioavailability, 
efficacy and toxicity profile to result 
in a candidate to be progressed to in 
vivo studies, in animals, and finally on 
humans.
 NMR will contribute heavily in all 
these phases will full characterization 
Figure 1
Figure 1: The drug discovery and development process.
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of the compound and solid state data, 
stability studies, formulation studies 
and NMR-based metabolomics 
experiments. All these aspects will be 
covered in a future contribution.
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What was the purpose of your 
research?
This study was initiated to compare 
the performance of three rather 
different Raman dispersive 
spectrometers in the measurement 
of an important class of uranium 
compound. This study is important 
for the application of Raman 
spectroscopy to nuclear forensics. The 
class of compound studied is uranium 
ore concentrates (UOC) and there are 
different compositions of UOCs. This 
study also included UO2 powder and 
UO2 nuclear fuel pellet.
What were the key results from your 
research?
The three Raman spectrometers 
were, the hand-held spectrometer 
(FirstDefender) from Ahura Scientific®, 
a bench-top spectrometer (Senterra) 
from Bruker® and a laboratory 
spectrometer (T64000) from HORIBA 
Jobin Yvon®. We found that the hand-
held Raman has good sensitivity (as 
defined in our paper) for five out of 
the seven compounds but it is unable 
to measure dark coloured powders 
such as UO2 and U3O8. Senterra 
has the best sensitivity for all the 
compounds measured.
 T64000 has the poorest sensitivity 
but best resolution and its signal-
to-noise ratio can be comparable to 
FirstDefender and Senterra. Figure 1 
illustrates the differences in sensitivity 
among the three spectrometers for 
the seven compounds measured.
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Whilst conducting this research, Doris Ho Mer 
Lin was a PhD student with the University of 
Heidelberg and Institute for Transuranium 
Elements. Her research was focused on the 
exploration of Raman spectroscopy and 
morphology as signatures for uranium ore 
concentrates for nuclear forensics purposes.
What does this actually mean?
Our current [1] and previous study 
[2] have demonstrated that Raman 
spectroscopy is a useful tool for the 
analysis of uranium ore concentrates 
for nuclear forensic purposes. Each 
spectrometer has its strength and 
limitations. Comparisons were made 
in terms of sensitivity, signal-to-noise 
and the ability to detect process-
related impurities.
 References
1. D. M. L. Ho, D. Manara, Zs. Varga, A. Berlizov, 
T. Fanghänel and K. Mayer, The use of different 
dispersive Raman spectrometers for the analysis of 
uranium compounds, Vibrational Spectroscopy, 73 
(2014) 102-110.
2. D. M. L. Ho, D. Manara, P. Lindqvist-Reis, 
T. Fanghänel and K. Mayer, Applicability of Raman
Spectroscopy as a Tool in Nuclear Forensics for 
Analysis of Uranium Ore Concentrates,
Radiochimica Acta, 101 (2013) 779-784.
Figure 1
Figure 1: Raman spectra of each compound measured by different spectrometers (normalised 
according to Equation 1 [2]). A = ammonium diuranate, B = sodium diuranate, C = UO2 powder, D = 
UO2 pellet, E =  U3O8, F = uranyl hydroxide, G = uranyl peroxide.
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Gary Ritchie, Director of Scientific Affairs, InfraTrac, Inc., Silver Spring, Maryland USA, answers questions on anti-counterfeiting approaches to product 
and packaging using chemical fingerprinting and Near-Infrared (NIR) Spectroscopy.
What was the purpose of your 
research?
Brand owners need effective ways 
to protect their products against 
counterfeiting. InfraTrac chemically 
tags products and packaging so 
that they can be quickly and easily 
authenticated in the field. The 
following procedures show some of 
the applications developed for several 
product and packaging types.
 These applications have been 
developed to provide brand 
protection for a host of materials: 
paperboard for packaging, computer 
chips used in computer-controlled 
devices, pharmaceutical aluminium 
vial tops for injectable medication 
and hard gelatin capsules. The 
patented methods employed involve 
a three-step process: developing 
formulations from commodity 
chemicals, applying them to the 
product or the packaging, and 
verifying that they exhibit the desired 
spectral absorption attributes.
 The applications shown in Figure 1 
have been developed to provide 
coatings for a host of materials 
ranging from paperboard for 
packaging, computer chips used 
in computer-controlled devices; 
pharmaceutical aluminium vial tops 
to hold medicines and hard gelatin 
capsules as carriers for medicines.
What were the key results from your 
research? 
For the coating of paperboard, four 
formulations were prepared at the 
5%, 15%, 20% and 30% level, applied 
to the paperboard, dried and then 
scanned by near-infrared (NIR) 
spectroscopy. Taggants for computer 
chips required exploration of a 
range of materials that needed to be 
temperature resistant and that also 
required UV curing in order to achieve 
the desired properties. Aluminium 
vial tops for pharmaceutical 
containers also required UV curing, 
but in addition had to also be able 
to withstand high temperature 
autoclaving and undergo irradiation 
for sterilization. Finally, we illustrate 
a unique film coating for tagging 
hard gelatin capsules. Note that other 
spectroscopies may be used, such 
as mid-infrared or Raman, but in this 
work we report specifically on the use 
of NIR.
 As can be shown in Figures 2–5, the 
results of this work show that there 
are specific differences between 
untagged and tagged packaging 
and products when seen in the 
near-infrared spectrum (700 nm – 
2500 nm), but are undetectable and 
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bands in the near-infrared NIR 
spectrum that allow detection when a 
NIR spectrometer is used to locate the 
presence of specific absorption bands 
arising only from the coating material. 
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invisible to the naked eye in the visible 
spectrum (400 nm to 800 nm). The 
presence of specific absorption bands 
that are not present in untagged 
packaging and products demonstrate 
the utility of the NIR methods for 
discriminating between packaging 
and products that have taggant 
material versus those that do not.
What does this actually mean?
InfraTrac uses commodity chemicals 
for the purpose of formulating 
taggants for coating packaging and 
product components. Commodity 
chemicals are widely available (not 
specialty chemicals) so they can be 
supplied in quantity as needed. There 
are minimal supply chain risks and 
the coating process can be massively 
scaled to accommodate the level 
of risk desired by the vendor. The 
formulations must exhibit a range of 
properties that are required for matrix 
compatibility, product or package 
life cycle stability, and for the explicit 
purpose of remaining undetected in 
the visible spectrum while exhibiting 
Figure 1
Figure 1: Schematic showing InfraTrac’s three-step process for specifying properties, selecting 
appropriate taggant(s) and refining application specifications for final implementation. As a result 
of this process, the product and packaging vendor gains the capability for DETECTING, TESTING, and 
REPORTING of suspected counterfeit product or packaging materials.
Figures 2–5
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